KR890000470A - 2,2-디메틸크로만-3-올 유도체, 그의 제조방법 및 그를 함유하는 약학 조성물 - Google Patents

2,2-디메틸크로만-3-올 유도체, 그의 제조방법 및 그를 함유하는 약학 조성물 Download PDF

Info

Publication number
KR890000470A
KR890000470A KR1019880007608A KR880007608A KR890000470A KR 890000470 A KR890000470 A KR 890000470A KR 1019880007608 A KR1019880007608 A KR 1019880007608A KR 880007608 A KR880007608 A KR 880007608A KR 890000470 A KR890000470 A KR 890000470A
Authority
KR
South Korea
Prior art keywords
group
dimethylchroman
trans
cyano
phosphono
Prior art date
Application number
KR1019880007608A
Other languages
English (en)
Inventor
가르시아 조르쥬
루 리샤르
니사또 디노
고띠에르 빠뜨릭
Original Assignee
미쉘드 아스
소시에떼아노님 사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8708830A external-priority patent/FR2617165B1/fr
Priority claimed from FR8800278A external-priority patent/FR2625744B1/fr
Priority claimed from FR8803064A external-priority patent/FR2628424B1/fr
Application filed by 미쉘드 아스, 소시에떼아노님 사노피 filed Critical 미쉘드 아스
Publication of KR890000470A publication Critical patent/KR890000470A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
    • C10L—FUELS NOT OTHERWISE PROVIDED FOR; NATURAL GAS; SYNTHETIC NATURAL GAS OBTAINED BY PROCESSES NOT COVERED BY SUBCLASSES C10G, C10K; LIQUEFIED PETROLEUM GAS; ADDING MATERIALS TO FUELS OR FIRES TO REDUCE SMOKE OR UNDESIRABLE DEPOSITS OR TO FACILITATE SOOT REMOVAL; FIRELIGHTERS
    • C10L1/00—Liquid carbonaceous fuels
    • C10L1/32—Liquid carbonaceous fuels consisting of coal-oil suspensions or aqueous emulsions or oil emulsions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

내용 없음

Description

2,2-디메틸크로만-3-올 유도체, 그의 제조방법 및 그를 함유하는 약학 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 하기 일반식(I)로 표시되는 트랜스-2,2-디메틸 크로만-3-올 유도체 및 그의 포스포노 또는 카르복실기의 약학적으로 수용 가능한 염.
    [식중 : -N 및 CO사이의 A는 -CH=CH-E=CH-기 또는기를 나타내고; -Z는 할로겐 또는 시아노, 아세틸, 트리플루오로아세틸, 니트로, 알킬티오, 카르복실, 포스포노, 디알콕시포스포릴 또는 알콕시카르보닐기를 나타내며, 이때 알킬티오 및 알콕시기는 1~3개의 탄소원자를 함유하며; -E는 질소원자 또는 C(R4)기를 나타내고; -R1은 수소, 메틸기 또는 히드록실기를 나타내고, R2및 R3는 각각 독립적으로 수소, 또는 메틸기를 나타내며, 이때 치환기 R1, R2, R3중 단 하나만이 메틸기일 수 있으며; -R4는 수소원자, 할로겐원자, 메틸기 또는 히드록실기를 나타낸다.]
  2. 제1항에 있어서, Z가 시아노기를 나타내는 트랜스 -2,2-디메틸크로만-3-을 유도체.
  3. 트랜스-6-시아노-4-(1,2-디히드로-2-옥소피리드-1-열)-2,2-디메틸크로만-3-올.
  4. 트랜스-6-시아노-4-(1,2-디히드로-4-히드록시-2-옥소피리드-1-일)-2,2-디메틸크로만-3-올.
  5. 트랜스-6-시아노-4-(1,6-디히드로-3-히드록시-6-옥소피리다진-1-일)(-2,2-디메틸크로만-3-올.
  6. 하기일반식(ii)의 크로만 에폭시드를 하기일반식(III)의 헤테로고리화합물로 처리하고, 적당하다면 알콕시카르보닐기를 카르복실기로, 또는 디알콕시포스포릴기를 포스포노기로 전환시키고, 적당하다면 수득된 카르복시산 또는 포스폰산을 그의 약학적으로 수요가능한 염으로 전환시킴을 특징으로 하는, 제1항~제5항중 어느 한항에 따른 화합물의 제조방법.
    [식중 Z′은 제1항의 Z에서 정의한 바와 같으나 카르복실기 또는 포스포노기는 아니며, A는 제1항에서 정의한 바와 같다.]
  7. 제1항~제5항중 어느 한항에 따른 2,2-디메틸크로만-3-을 유도체를 활성성분으로 함유하는 약학 조성물.
  8. 제7항에 있어서, 약학 부형제와 혼합된 투여단위당 0.5~200mg의 활성 성분을 함유하는 약학 조성물.
  9. 하기일반식(I)의 트랜스 -2,2-디메틸크로만을 유도체 및 그의 포스포노 또는 카르복실기의 약학적으로 수용 가능한 염의 항부정맥 및 항고혈압 활성을 갖는 약학 조성물의 제조를 위한 용도.
    [식중 : -N과 CO사이의 A는 -CH=CH-E=CH-기 또는기를 나타내고; -Z는 할로겐 또는 시아노, 아세틸, 트리플루오로아세틸, 니트로, 알킬티오, 카르복실, 포스포노, 디알콕시포스포릴 또는 알콕시카르보닐기를 나타내며, 이때 알킬티오 및 알콕시기는 1~3개의 탄소원자를 함유하며; -E는 질소원자 또는 C(R4)기를 나타내고; -R1은 수소, 메틸기 또는 히드록실기를 나타내고, R2및 R3는 각각 독립적으로 수소 또는 메틸기를 나타내며, 치환기 R1, R2, R3중 단 하나만이 메틸기일 수 있으며; -R4는 수소원자, 할로겐원자, 메틸기 또는 히드록실기를 나타낸다.]
    ※참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880007608A 1987-06-23 1988-06-23 2,2-디메틸크로만-3-올 유도체, 그의 제조방법 및 그를 함유하는 약학 조성물 KR890000470A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
FR8708830 1987-06-23
FR8708830A FR2617165B1 (fr) 1987-06-23 1987-06-23 Derives du dimethyl-2, 2 chromannol-3
FR8800278 1988-01-12
FR8800278A FR2625744B1 (fr) 1988-01-12 1988-01-12 Derives du dimethyl-2,2 chromannol-3 procede d'obtention et compositions pharmaceutiques en contenant
FR8803064 1988-03-09
FR8803064A FR2628424B1 (fr) 1988-03-09 1988-03-09 Derives du dimethyl-2,2 chromannol-3 procede d'obtention et compositions pharmaceutiques en contenant

Publications (1)

Publication Number Publication Date
KR890000470A true KR890000470A (ko) 1989-03-14

Family

ID=27251476

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880007608A KR890000470A (ko) 1987-06-23 1988-06-23 2,2-디메틸크로만-3-올 유도체, 그의 제조방법 및 그를 함유하는 약학 조성물

Country Status (9)

Country Link
EP (1) EP0296975A1 (ko)
JP (1) JPS6426578A (ko)
KR (1) KR890000470A (ko)
DK (1) DK343388A (ko)
FI (1) FI90343C (ko)
IL (1) IL86798A (ko)
NO (1) NO170216C (ko)
NZ (1) NZ225117A (ko)
PT (1) PT87788B (ko)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387587A (en) * 1986-12-23 1995-02-07 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
DE3726261A1 (de) * 1986-12-23 1988-07-07 Merck Patent Gmbh Chromanderivate
US5284838A (en) * 1987-06-23 1994-02-08 Elf Sanofi Use of 2,2-dimethylchroman-3-ol derivatives in the treatment of asthma
US4971982A (en) * 1987-07-06 1990-11-20 Hoffmann-La Roche Inc. Benzopyran derivatives
US5021432A (en) * 1988-04-26 1991-06-04 Yoshitomi Pharmaceutical Industries, Ltd. Benzopyran compound and its pharmaceutical use
JPH03500542A (ja) * 1988-05-09 1991-02-07 ビーチャム　グループ　ピーエルシー 新規な化合物及び治療法
US5254557A (en) * 1988-05-09 1993-10-19 Beecham Group P.L.C. Compound and treatment
DE3837809A1 (de) * 1988-11-08 1990-05-10 Merck Patent Gmbh Tetralinderivate
ATE120459T1 (de) * 1988-12-13 1995-04-15 Beecham Group Plc Benzopyran und verwandte verbindungen.
US5239090A (en) * 1989-02-01 1993-08-24 Beecham Group P.L.C. Certain optically active 3,4-dihydrobenzopyran-4-ols which are intermediates
GB8902118D0 (en) * 1989-02-01 1989-03-22 Beecham Group Plc Chemical process
US5162553A (en) * 1989-03-03 1992-11-10 Yoshitomi Pharmaceutical Industries, Ltd. Processes for preparing optically active 3,4-dihydro-3,4-epoxy-2H-1-benzopyran compounds and intermediates therefor
US5066816A (en) * 1989-03-03 1991-11-19 Yoshitomi Pharmaceutical Industries, Ltd. Processes for preparing optically active 3,4-dihydro-3,4-epoxy-2h-1-benzopyran compounds and intermediates therefor
FR2645021A1 (fr) * 1989-03-30 1990-10-05 Sanofi Sa Utilisation d'un agoniste potassique dans le traitement du glaucome
DE3923839A1 (de) * 1989-07-19 1991-01-31 Beiersdorf Ag Benzopyran-derivate, verfahren zu ihrer herstellung und ihre verwendung sowie die verbindungen enthaltende zubereitungen
GB8916683D0 (en) * 1989-07-21 1989-09-06 Beecham Group Plc Novel compounds
DE3924417A1 (de) * 1989-07-24 1991-01-31 Merck Patent Gmbh Chromanderivate
DE3926001A1 (de) * 1989-08-05 1991-02-07 Merck Patent Gmbh Chromanderivate
US5185345A (en) * 1989-11-06 1993-02-09 Sanofi 4-amidino pyrano (3,2-c) pyridine derivatives, and pharmaceutical compositions containing them
FR2657872B2 (fr) * 1989-11-06 1992-06-12 Sanofi Sa Derive d'amidino-4 chromanne, procede d'obtention et compositions pharmaceutiques le contenant.
FR2654103B1 (fr) * 1989-11-06 1992-02-21 Sanofi Sa Derives d'amidino-4 chromanne, procede d'obtention et compositions pharmaceutiques les contenant.
DE4115465A1 (de) * 1991-05-11 1992-11-12 Beiersdorf Ag Neue in 4-stellung durch aryl oder n-heteroaryl substituierte 2h-benzo(b)pyran-derivate, verfahren zu ihrer herstellung und ihre verwendung sowie die verbindungen enthaltende zubereitungen
RU94030464A (ru) * 1991-12-05 1996-04-27 Смитклайн Бичам Плс (Gb) Фармацевтическая композиция, способ ее получения, способ лечения заболеваний дыхательных путей, применение фармацевтической композиции
GB9203596D0 (en) * 1992-02-20 1992-04-08 Smithkline Beecham Plc Novel process
GB9207400D0 (en) * 1992-04-02 1992-05-13 Smithkline Beecham Plc Novel use
CN1044605C (zh) * 1992-08-17 1999-08-11 中外制药株式会社 苯并吡喃和苯并嗪衍生物
US6031115A (en) * 1993-05-14 2000-02-29 Smithkline Beecham Plc Process for preparing epoxides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3274350D1 (en) * 1981-09-25 1987-01-08 Beecham Group Plc Pharmaceutically active benzopyran compounds
EP0107423B1 (en) * 1982-10-19 1986-07-23 Beecham Group Plc Novel chromans and chromenes
EP0172352B1 (en) * 1984-06-22 1990-08-29 Beecham Group Plc Active benzopyran compounds
DE3726261A1 (de) * 1986-12-23 1988-07-07 Merck Patent Gmbh Chromanderivate

Also Published As

Publication number Publication date
DK343388A (da) 1988-12-24
DK343388D0 (da) 1988-06-22
NO882762D0 (no) 1988-06-22
FI882945A0 (fi) 1988-06-20
FI882945A (fi) 1988-12-24
NO170216B (no) 1992-06-15
NZ225117A (en) 1990-02-26
JPS6426578A (en) 1989-01-27
PT87788B (pt) 1992-10-30
EP0296975A1 (fr) 1988-12-28
FI90343B (fi) 1993-10-15
IL86798A0 (en) 1988-11-30
NO882762L (no) 1988-12-27
FI90343C (fi) 1994-01-25
NO170216C (no) 1992-09-23
PT87788A (pt) 1988-07-01
IL86798A (en) 1992-12-01

Similar Documents

Publication Publication Date Title
KR890000470A (ko) 2,2-디메틸크로만-3-올 유도체, 그의 제조방법 및 그를 함유하는 약학 조성물
NZ196284A (en) 1-piperazino-3-phenylindane derivatives:pharmaceutical compositions
FR2639349B1 (fr) Nouveaux derives du chromane actifs sur le systeme nerveux central, leur procede de preparation et les compositions pharmaceutiques en contenant
KR900014396A (ko) 티에노-트리아졸로-디아제핀 유도체, 그의 제조 방법 및 그를 함유하는 치료 조성물
KR910009672A (ko) 피리다진 유도체, 이의 제조방법 및 이것을 함유하는 약학 조성물
KR890006625A (ko) 2,2-디메틸크로멘 유도체, 그의 제조방법 및 그것을 함유하는 약학 조성물
EP0219852A3 (en) Chartreusin derivatives, salts thereof, antitumorous compositions containing the same, and processes for producing the same
FR2681864B1 (fr) Nouveaux derives bicycliques azotes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
KR900014397A (ko) 티에노-트리아졸로-디아제핀 술포닐 유도체, 그의 제조 방법 및 그를 함유하는 치료 조성물
AU526978B2 (en) Tetracyclic indole derivatives
YU158385A (en) Process for obtaining derivatives of 2-pyridine thioles
KR880013896A (ko) 벤조푸로[3,2-c]퀴놀린 화합물
FI892685A0 (fi) Menetelmä uusien, sytostaattisesti vaikuttavien antrasykliinijohdannaisten valmistamiseksi
KR880001630A (ko) 5-플루오로우라실 유도체 및 그의 용도
ATE95180T1 (de) Berbanderivate und ihre herstellung und pharmazeutische zubereitung.
SE8804696L (sv) Dioxazocin- derivat, deras framstaellning och beredningar innehaallande desamma
KR930001906A (ko) 벤즈이미다졸린-2-옥소-1-카복실산 유도체의 용도
KR870001153A (ko) 디페녹시에틸아민 유도체가 함유된 약제조성물 및 그의 생산방법
ATE25968T1 (de) 1,1-diphenylpropanol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ES485333A1 (es) Procedimiento para preparar derivados 5,6,7,8-tetrahidro-4 (3h)-quinazolinonicos y sus sales
SE8405332L (sv) 2h-azeto (2,1-a)-isokinolinderivat, forfarande for deras framstellning och farmaceutiska kompositioner innehallande dem

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
E902 Notification of reason for refusal
E601 Decision to refuse application